Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Body Dysmorphic Disorder
NCT04656301Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Feb 2021
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in body dysmorphic disorder (BDD), sponsored by New York State Psychiatric Institute. Started Feb 2021; status: completed.
02
Drugs
psilocybin
03
Conditions
body dysmorphic disorder (BDD)
Beyond the preview
Go deeper on NCT04656301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656301.